Cardiovascular-renal disease is the leading cause of death worldwide resulting in a massive societal burden. However, in recent years, we have seen a decline in the number of innovative cardiovascular treatments entering the marketing place. Why has the rate of development for new drugs in cardiovascular declined and what can be done to reverse this trend? This session will focus on strategies to tackle cardiovascular-renal diseases. Strategies to accelerate drug development in order to get treatments to patients quicker and more efficiently will be addressed, including incorporating digital health as an accelerator.